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Liver TransplantationThe Effect and Safety of Prostaglandin
Administration in Pediatric Liver Transplantation
Céline Lironi, MD,1 Valérie A. McLin, MD,2 and Barbara E. Wildhaber, MD1
Background. Prostaglandins are often administered after liver transplantation (LT) to diminish ischemia-reperfusion injury (IRI),
to favor liver recovery and to prevent vascular thrombosis. Possible beneficial effects in adult liver recipients are controversial, but
the single existing pediatric small case series shows no significant impact of prostaglandin administration after LT. The purpose of
this study was to analyze the effect of the prostaglandin dinoprostone in pediatric liver recipients.Methods.A retrospective anal-
ysis of 41 children (<16 years) who underwent LT between March 2008 and December 2013 was performed. Dinoprostone was
administered at a rate from 0.1 to a maximum of 0.6 μg/kg per hour immediately after LTand for a maximum of 5 days. Effect of
dinoprostone on post-LT IRI and hepatic function up to 60 postoperative days and number of hypotensive episodes were ana-
lyzed.Results. The median cumulative dose of dinoprostone was 28 μg/kg (interquartile range, 23.2). Dinoprostone had no sig-
nificant effect on post-LT liver function tests and factor V levels at any of the administered dosages. There was no significant
association between the total quantity of vasopressor given and the number of hypotensive episodes observed in 8 patients.
One patient showed a short-lasting hypotension, possibly related to the administration of dinoprostone. Conclusions. This
study did not show, at any dosage between 0.1 and 0.6 μg/kg per hour, any differences in beneficial or harmful effects of high-
or low-dose dinoprostone administered immediately after pediatric LTon markers of IRI, hepatic function, or hypotension.
(Transplantation Direct 2017;3: e163; doi: 10.1097/TXD.0000000000000682. Published online 18 May, 2017.)Ischemia-reperfusion injuries (IRI) take place right after thereperfusion of the anoxic, transplanted liver, due to mas-
sive production of oxygen radicals and cytokines, toxic for
endothelial and parenchymal cells.1 Prostaglandins E (PGE)
have been shown to have a direct and indirect cytoprotective
effect on hepatocytes and sinusoidal endothelial cells by
preventing IRI after liver transplantation (LT).2,3 Of particular
interest in organ transplantation, PGE have been shown to have
an immunomodulatory effect and to enhance regeneration.3Received 3 January 2017. Revision requested 9 April 2017.
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Transplantation DIRECT ■ 2017PGE further induce vasodilatation and inhibit thrombocyte ag-
gregation, which theoretically might improve hepatic perfusion
and portal circulation, and thus decrease the risk of vascular
thrombosis4: this is the rationale for the use of PGE in LT. Stud-
ies in adult patients have examined the benefit of PGE adminis-
tration in the immediate postoperative period with the aim of
improving the recovery of liver function,5-7 decreasing pri-
mary nonfunction,1,6,8 and avoiding vascular thrombosis,4
These studies resulted in diverging conclusions.8-11 There is
only 1 small pediatric study that shows no effect on
ischemia-reperfusion or on vascular complications.12
Our center routinely uses dinoprostone during the first
5 days after LT. The aim of this study was to retrospectively
analyze the effect of dinoprostone on markers of IRI (an in-
crease in alanine aminotransferase (ALT), aspartate amino-
transferase (AST), bilirubin, and gamma-glutamyl transferase
(γGT)13), on the recovery of liver function post-LT (factor V
levels and international normalized ratio (INR)7), on the rate
of vascular complications, and on the prevalence of side effects
such as the safety of administration, bymonitoring blood pres-
sure, because hypotension is known to be a major side effect.
MATERIALS AND METHODS
Patient Cohort
Children aged 0 to 16 years who underwent LT in our cen-
ter fromMarch 2008 toDecember 2013were included. They
were listed for LT, when they met 1 or more of the following
criteria: (i) in patients with liver cirrhosis: rising serum biliru-
bin levels, repetitive episodes of cholangitis, worsening portalwww.transplantationdirect.com 1
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with metabolic disease: failure to thrive, problems in disease
management, severe impairment of quality of life.
PGEwas administered to have the patients benefit from its
cytoprotective and regenerative effect and to help to avoid he-
patic artery thrombosis by its effect on vasodilatation and
thrombocyte aggregation. PGE was given to any child with
the same dosage regimen, without considering the graft type
(whole vs split), indication for LT, or severity of pre-LT portal
hypertension. Patients received continuous dinoprostone in-
travenously immediately after surgery, that is, 2 hours after
closure of the abdomen, starting at 0.1 μg/kg per hour, in-
creasing the dose every 6 hours as tolerated (ie, no increase
if hypotension) to a maximal 0.6 μg/kg per hour, for a dura-
tion of 5 days. Treatment was stopped for the following rea-
sons: (a) completion of a 5-day infusion, (b) early discharge
to the floor, (c) hypotensive episode temporally related to in-
crease in dinoprostone dose.
This study was approved by the Ethical Committee of the
UniversityHospitals of Geneva (CER11-10R) and parents of
the analyzed patients provided informed written consent be-
fore the study.
Outcome Measures
Data were collected from the individual electronic patient
charts. The following variables were recorded: demographic
data of patients, donors and grafts at time of LT, periopera-
tive data, post-LT laboratory data at days 1, 3, 5, 10, 30,
and 60 post-LT, complications, defined as an adverse event
arising within 4 weeks post-LT, vasoactive drugs or vasopressors
administered in the intensive care unit (cumulative dose during
5 days post-LT for (nor)epinephrine, dobutamine, dopamine,
niprussiate, nifedipine, and enalapril). For the purpose of sta-
tistical analysis, patients were divided into 2 categories “no
drug given” and “1 dose of any drug.”Hypotension was de-
fined as an episode of a mean arterial pressure below the fifth
percentile for age; the number of hypotensive episodes during
the first 5 days post-LTwas recorded.
Selection criteria for grafts were maximal accepted donor
age not more than 50 years older than the recipient, maximal
BMI 25, biological parameters had to show an improving
trend from admission to procurement, sodium levels less than
160 μmol/L, and liver steatosis on ultrasound had to be esti-
mated as less than 10%.
Statistics
Cross-Sectional Analysis
Associations between the cumulative doses of dinoprostone
at day 5 post-LT and the outcome parameters were examined
visually using a scatterplot. These associations were quantified
using the Spearman correlation, this analysis being robust to
extreme values. We then stratified children into 2 groups, hav-
ing received more or less than 28 μg/kg of dinoprostone as a
cumulative dose. 28 μg/kgwas themedian of the entire cohort.
Results were considered statistically significant if they reached
a P value less than 0.05.
Longitudinal Analysis
To evaluate the course of the outcomes according to the
cumulative dose of dinoprostone given after LT, we first repre-
sented the evolution of each outcome factor over time, in func-
tion of each single (noncumulative) dose of dinoprostone. Amultivariate analysis using the same model was carried out
while adjusting for the effect of dinoprostone on model for
end-stage liver disease score (MELD), patient’s weight (z score),
primary disease (biliary atresia [BA] vs others) over time. The
Spearman correlation coefficient was also used to assess the
association between the cumulative dose of dinoprostone
and the use of vasopressors (per day and until day 5 post-LT).
RESULTS
One of the 41 patients was excluded because of an aber-
rant, unreasonable value of cumulative dinoprostone dose,
most probably due to an error in data recording. Patient
characteristics for each treatment group are summarized in
Table 1. The 2 groups differed in the need for emergency
for LT, the type of liver graft, and the primary disease. For
the latter, statistics were adjusted during further analysis.
There was no early vascular complication. Therefore, analy-
sis of this outcome measure was not possible.
Cross-Sectional Analysis
No significant correlation was observed between the cumu-
lative dinoprostone dose and all analyzed outcome variables
(AST, ALT, yGT, bilirubin, INR, factor V) up to 60 days after
LT (Table 2, Figure 1). There was no difference in outcome
5 days post-LT between the group having received less than
28 μg/kg and that having received greater than 28 μg/kg of
cumulative dinoprostone dose (Table 3).
Longitudinal Analysis
No significant correlation was observed between each sin-
gle dinoprostone dose and all outcome variables analyzed
over the entire observed period of 60 days (AST, ALT, yGT,
bilirubin, INR, factor V). Results remain nonsignificant
when adjusted for the possible confounding factors: pre-LT
MELD, primary disease (BA vs others) and weight z score
(Table 4, Figure 2).
Patient and Graft Survival
The overall 5-year patient survival was 95%, with 1 death
in each group, 1 due to an overwhelming adenovirus infection,
and the other patient due to multiple organ failure in a super
urgent setting. Overall 5-year graft survival was 92.5%; there
was a 90% 5-year graft survival in the group having received
less than 28 μg/kg of cumulative dinoprostone dose, and a
95%5-year graft survival in the group having received greater
than 28 μg/kg, with no significant difference.
Adverse Events: Patients With Hypotension
Eight (20%) of 40 patients experienced hypotensive epi-
sodes, without measurable sequelae. These patients are sum-
marized in Table 5: 4 of 8 patients had a clear reason for their
hypotension, 2 of 8 remained unclear, 2 of 8 had received an
antihypertensive drug overdose, and 1 of 8 hypotensive epi-
sode might have been due to an increase of dinoprostone.
No association was found between the number of hypoten-
sive events and the quantity of administered vasopressors.
DISCUSSION
This study aimed to determine the influence of dino-
prostone on markers of IRI, the recovery of liver function af-
ter LT, the rate of vascular complications and the side effects
of administering dinoprostone in a cohort of pediatric liver
transplant recipients. We did not show, at any dosage of
TABLE 1.









Male 21 (52) 13 8 ns
Female 19 (48) 7 12
Blood group
A 39 (98) 19 20 ns
B 0 (0) 0 0
O 1 (2) 1 0
Primary disease
BA 22 (55) 7 15 0.03
Others 18 (45) 13 5
Type of grafta
Split liver 24 (60) 15 9 0.005
Whole liver 13 (33) 2 11
Living donor 3 (7) 3 0
Blood group compatibility
Identical 26 (65) 12 14 ns
Compatible 13 (33) 7 6
Incompatible 1 (3) 1 0
Type of emergency
Elective 26 (67) 11 15 0.02
Urgent 3 (8) 8 2
Super-urgent 10 (26) 0 3
Infection post-LT
None 25 (62) 13 12 ns
Bacterial 11 (28) 5 6
Viral 4 (10) 2 2
Acute rejection post-LT (<4 wk) 11 (28) 7 4 ns
Primary nonfunction 0 0 0 ns
Vascular complications post-LT 0 (0) 0 0 n/a
Median (IQR):
PELD 14 (22) 16 (27) 10 (21) ns
Age at LT, y 1.2 (3.4) 1.5 (8.3) 1.1 (3.0) ns
Height at LT, cm 76 (36) 78 (63) 75 (24) ns
Weight at LT, kg 9.8 (10.1) 10.0 (17.0) 9.8 (6.5) ns
Weight (z score) at LT −0.9 (2.1) −1.3 (2.5) −0.6 (1.4) ns
Creatinine before LT, μmol/L 21 (16) 23 (19) 19 (15) ns
INR before LT 1.3 (0.9) 1.4 (1.3) 1.3 (0.6) ns
γGT before LT, U/L 76 (145) 69 (217) 86 (126) ns
Total bilirubin before LT, μmol/L 79 (340) 151 (342) 69 (331) ns
Donor age, y 19 (30) 22 (20) 16 (32) ns
Total ischemia time, hb 1.3 (5.7) 1.1 (6.3) 2.1 (4.2) ns
Red blood cell transfusion, mL 680 (924) 1006 (1633) 490 (1633) ns
a All of them heart-beating donors.
b Defined as the sum of cold and warm ischemia times.
IQR, interquartile range; ns, not significant; n/a, not applicable; PELD, pediatric end-stage liver disease score. TABLE 2.
Cross-sectional analysis of the cumulative dose of
dinoprostone for each variable
Analyzed parameters Spearman correlation P
AST, U/L −0.09 0.57
ALT, U/L 0.10 0.52
yGT, U/L −0.03 0.85
Bilirubin, μmol/L −0.25 0.13
INR 0.12 0.58
Factor V, % −0.31 0.12
There was no significant correlation between doses of cumulative dinoprostone and all analyzed out-
come variables up to 60 days after LT.
© 2017 Wolters Kluwer Lironi et al 3dinoprostone between 0.1 and 0.6 μg/kg per hour, over
5 days, any difference in beneficial or harmful effects of
high- or low-dose dinoprostone administered immediately
after pediatric LT.
IRI is thought to be one of the etiologic factors of graft pri-
mary nonfunction.13 In 1989, Greig et al were the first to
show a significant decrease of mortality in a group of patients
with primary nonfunction treated with PGE (10 patients) in
comparison with nontreated patients (6 patients), in a cohort
of 82 patients (18 children and 64 adults). Yet, later on, themajority of studies did not support a direct effect of PGE
on primary nonfunction.5,6,8,11,12,14,15 In our study, there
was no primary nonfunction event; therefore, the effect of
dinoprostone could not be evaluated. Greig et al13 also
showed a more rapid decrease of AST and ALT. In 1997,
Giostra et al1 confirmed these findings and also revealed a
cytoprotective effect of PGE (significant decrease of transam-
inases and of bilirubin) in 38 adults. The effect was limited to
the first 5 days after LT, and thereafter aminotransferase
levels and mortality rates were similar in the treatment and
control groups. Another study confirmed that in case of
posttransplant elevated hepatic artery resistive index (>0.75),
a sign of IRI, the administration of PGE led to a significant re-
duction of transaminases and a decline of the resistive index.16
In contrast to these positive studies, Alevizacos et al5 showed, in
a randomized prospective study, the absence of a cytoprotective
effect of PGE after administration for 3 days: the control group
had lower ischemia reperfusion parameters than the treated
group, and no significant difference in prothrombin time was
observed between the control and treatment group. Another
study failed to show a difference of bilirubin and γGT levels be-
tween groups receiving or not PGE during 14 days after LT.10
These findings are supported by our study, where we observed
no significant trend of transaminases, nor bilirubin or γGTwith
increasing cumulative dose of dinoprostone.
The aim of trying to reduce IRI is to improve hepatic func-
tion. Indeed, Greig et al13 showed a positive effect on liver
function with a more rapid rise of coagulation factors (V and
VII) and prothrombin time. Kornberg et al10 confirmed an im-
proved liver function after PGE treatment: factor Vwas signif-
icantly higher in the first 2 days postsurgery in the treatment
group (a group that had a high hepatic arterial resistance index
(>0.75) and therefore was treated) in comparison to the con-
trol group. These results are even more valuable, because the
group receiving PGE had indirect signs of severe IRI. In the
present study, the effect of PGE did not seem to confer an ad-
vantage for the recovery of liver function as measured by fac-
tor Vand INR.
Graft type and type of emergencymight have an important
influence on outcomes in this cohort. Whole livers displayed
more rapid recovery of synthetic hepatic function. A positive
cumulative effect of whole liver grafts together with a higher
dose of cumulative dinoprostone, as in our study,was probable,
but thiswas not observed.Nonemergent LTare also expected to
have better immediate outcome parameters, because the patient
usually is in a more stable condition. Emergency LT together
with a lower dose of cumulative dinoprostone might come
FIGURE 1. Transversal scatterplot analyses of the cumulative dose of dinoprostone on: A, ALT; B, γGT; C, INR; D, Factor V (%) at day 5 after
LT. There was no significant correlation with the measured outcome parameters.
TABLE 3.
Comparison of outcome parameters 5 days after LT between
the 2 patient groups
Analyzed parameters Group <28 μg/kga Group >28 μg/kga P
AST, U/L 119.5 92.2 0.25
ALT, U/L 378.1 457.5 0.54
yGT, U/L 182.7 151.1 0.52
Bilirubin, μmol/L 112.2 69.7 0.13
INR 1.1 1.2 0.32
Factor V, % 98.8 90.5 0.06
a Cumulative dinoprostone dose of < or >28 μg/kg body weight.
Outcome variables at day 5 after LT were not statistically different.
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fied in our study.
PGEwas given to any child with the same dosage regimen,
without considering the graft types or indications for LT, and
treatment was only stopped before the 5-day completion of
the infusion if hypotensive episodes were recorded and con-
sidered to be due to an increase in dinoprostone dose. Thus,
the observed statistical differences between the 2 groups, with
more BA patients, elective and whole graft recipients receiving
higher doses, are not to be seen as related with a deliberate
high or low dose PGE dosage.
The side effects associated with the administration of
dinoprostone were evaluated bymonitoring for hypotension.
We only identified a single patient, who seemed to have hy-
potensive episodes linked to a dose increase, which re-
sponded to dose reduction. The evaluation, if hypotensive
events were camouflaged by the administration of vasopres-
sors, revealed no correlation. We conclude that administra-
tion of dinoprostone in children with doses of no more
than 0.6 μg/kg per hour appears to be safe.
To our knowledge, only 1 exclusively pediatric study exists
on the preventive administration of PGE after LT: Bucuvalas
et al,12 in 2001, combined PGE andN-acetylcysteine with theaim to reduce IRI. Their study did not show any significant
difference in patient and graft survivals, allograft rejection
within the first 90 days after LT, peak concentration of serum
ALT posttransplant, post-LT length of hospitalization, post-
operative complications, as well as no adverse events of
PGE between the treated group (12 patients) and the control
group (13 patients). In our present study, where all study
TABLE 4.
Longitudinal analysis of the effect of the cumulative dose of dinoprostone after LT on outcome variables over the
observation period
Univariate (dinoprostone and time) Adjusted for MELD, primary disease, weight z score
Analyzed parameters Coefficient P Coefficient P
AST, U/L −6.5 0.50 −5.1 0.61
ALT, U/L −4.6 0.30 −4.9 0.29
yGT, U/L −1.3 0.14 −0.9 0.29
Bilirubin, μmol/L −0.2 0.77 −0.5 0.43
INR 0.0 0.68 0.0 0.46
Factor V, % −0.05 0.79 −0.05 0.77
With and without adjustment for confounders there was no significant correlation.
© 2017 Wolters Kluwer Lironi et al 5patients have got PGE, we found that with any dosage of
dinoprostone between 0.1 and 0.6 μg/kg per hour, there
was no observable trend of impact on IRI, hepatic function
or hypotensive episodes. Because it is not known what isFIGURE 2. Longitudinal analyses of each single dose of dinoprostone o
easier visualization, patients were stratified into 2 groups of cumulative dos
body weight. There was no significant correlation with the measured outcthe best dose of PGE in pediatric patients, it could be that
the best dose would be even lower or higher.
Although the cohort is measurably larger than in the previ-
ous study, it is small and the following weaknesses should ben: A, ALT; B, γGT; C, INR; D, Factor V (%) up to 60 days after LT. For
e of dinoprostone having received less than and greater than 28 μg/kg
ome parameters up to day 60.
TABLE 5.




Cumulative dose of dinoprostone
at the moment of hypotension Cause of hypotension Treatment
5 D1 3.1 μg/kg per 24 h Increase of dinoprostone Reduction of dinoprostone
D2 5.0 μg/kg per 24 h
D4 4.7 μg/kg per 24 h
7 D5 Stopped 2D before Undetermined (stop of dinoprostone at day 3) IV bolus
14 D4 13.8 μg/kg per 24 h Probably overtreatment with antihypertensive medication Reduction of antihypertensive medication
17 D1 3.6 μg/kg per 24 h Hypovolemia due to an important postoperative capillary leakage IV bolus
30 D1 5.8 μg/kg per 24 h Probably overtreatment with antihypertensive medication Stop of antihypertensive treatment + vasopressors
D2 6.0 μg/kg per 24 h
35 D1 1.5 μg/kg per 24 h Septicemia IV bolus
D4 6.6 μg/kg per 24 h
39 D3 9.6 μg/kg per 24 h Allergic reaction to hydroxyethylamidone (Voluven) IV bolus + vasopressors
41 D1 1.4 μg/kg per 24 h Undetermined IV bolus
D2 6.5 μg/kg per 24 h
One of 8 hypotensive episode might have been due to an increase of dinoprostone. Four of 8 patients had a clear reason for their hypotension. Two of 8 remained unclear. Two of 8 received an (over)treatment with
antihypertensive drugs.
D, postoperative day; IV, intravenous.
6 Transplantation DIRECT ■ 2017 www.transplantationdirect.comconsidered in examining the findings. The 2 groups (cumula-
tive dose of dinoprostone of <28 and >28 μg/kg) are not identi-
cal, and notably show significant differences as to the primary
disease (more BApatients in the groupwith >28μg/kg), the type
of emergency (more emergent LT in the group with <28 μg/kg)
and graft type (more whole liver grafts in the group >28 μg/kg).
Although these differences were accounted for in a post hoc
analysis, there was no significant difference in the effect of
dinoprostone on graft outcomes. A control group is neces-
sary to conclusively analyze effects of PGE. This study is
clearly of observational character and only gives a prelimi-
nary insight into the topic.
In summary, the present pediatric analysis, in agreementwith
other studies, failed to demonstrate a significant cytoprotective
effect of dinoprostone and no effect on recovery of liver func-
tion during the immediate postoperative period after LT at
dosages between 0.1 and 0.6 μg/kg per hour.5,8,11,12,14 A
2011 Cochrane analysis reported an important risk of bias
in most trials reviewed.15 An expensive multicenter con-
trolled study should be carried out, yet on a drug that has
fairly consistently failed to show benefit, and thus is highly
unlikely to be realized.
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